You are here

Validation of Cross-Species Biomarkers of DNA Damage

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 4R44ES028163-02
Agency Tracking Number: R44ES028163
Amount: $1,246,448.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: 113
Solicitation Number: PA16-302
Solicitation Year: 2016
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-09-01
Award End Date (Contract End Date): 2020-08-31
Small Business Information
Rochester, NY 14623-2860
United States
DUNS: 085992055
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 (585) 442-0930
Business Contact
Phone: (585) 442-0930
Research Institution

Project Summary This project will validate two high throughput human blood based DNA damage assays and develop them into commercial kitsThe assays monitor types of damage associated with important human diseasesWhereas the PIG A assay reports on gene mutationthe micronucleated reticulocyteMN RETassay is responsive to chromosomal breaks and or lossesThe biomarkers are applicable to both humans and laboratory animals and will fulfill two important needsextension of findings in laboratory animal models to direct studies in humansand performance of well controlled mechanistic laboratory studies to understand observations first made in humansThe assays utilize immunomagnetic separation prior to flow cytometry to dramatically enrich the relevant cell populations and thereby enhance assay precision and sensitivityBy providing simple to use kits with thoroughly documented reproducibility and inter laboratory transferabilityand validating the biomarkers for specific usesresearchers will have available tools with unprecedented efficiencies for comprehensively studying those factors that contribute to inter individual differences in human DNA damageApplications include the study of drug treatmentshost and or life style factors that contribute to inter individual differences in DNA damage and repairexaggerated sensitivities to antineoplastic therapiesand population based epidemiology studies of environmental exposuresincluding occupational exposuresThe project benefits from a strong multidisciplinary team of internationally recognized scientists with a proven track record of successfully converting research advances into reliable commercial assay kits Project Narrative This project will validate two high throughput human blood based DNA damage assays and develop them into commercial kitsThe assays represent significant advances in the ability to directly monitor important types of DNA damage in humansand their cross species nature is ideal for supporting mechanistic laboratory studies when necessaryValidation work will include but is not limited to assessments of assay reproducibility within and among laboratoriesvalidation of target cellsand identification of physiological and lifestyle factors that affect assay resultsThe proposed work also includes the evaluation of several important use cases for these kitsfor example studying DNA damage resulting from chemotherapiesand also systemic inflammation

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government